Sam Brusco, Associate Editor06.06.23
BD (Becton Dickinson) held a grand opening ceremony last week for a new €4 million research and development facility in Blackrock, Dublin and announced a further €30 million investment to expand its Enniscothy, Wexford manufacturing facility. The two investments will create over 85 new jobs in Ireland.
The new 10,600 square-foot Blackrock R&D facility will house 35 high-tech workers and complements BD’s Limerick R&D facility, which employs over 300 people. The Blackrock R&D facility, according to the company, will focus on commercializing BD’s first on-body injection device, the BD Evolve on-body injector. The facility will also be the regional base of operations for BD’s sales, technical service, and corporate functional support teams.
The new €30 million investment to expand its existing Enniscorthy manufacturing facility will create about 85 new jobs. The 40,000 square-foot expansion will house operations to manufacture a new technology from BD’s Peripheral Intervention business.
Minister of State for the Department of Enterprise, Trade and Employment Neale Richmond TD told the press, “I am delighted with BD's announcement of a €4 million research and development facility in Blackrock, Dublin and additional €30 million expansion investment in Enniscorthy, Wexford. The projects will create more than 85 new jobs in Ireland with opportunities for our talented workforce to be part of exciting new medical advancements at BD. It is of course always great to see regional job creation, and the Government are always hugely supportive of such announcements. Thanks to all the executives at BD for your continued investment and trust in Ireland. I wish all the team the very best with both projects.”
IDA Ireland CEO Michael Lohan added, “BD has had a presence in Ireland for over 50 years, and these significant investments, adding a further 85 jobs and new facilities to its already substantial Irish operations and jobs, underscores the strategic importance of Ireland in BD’s global operations. It is proof of the company’s future commitment to the country and testament to Ireland and indeed our region’s continued attractiveness as a location for investment. I wish to assure BD of IDA Ireland’s continued support.’’
President of BD for Europe, Middle East and Africa Roland Goette said, “BD first established operations in Ireland in 1964, and since then has grown to four locations that employ more than 1,100 people across the country. Ireland has proven to be a smart place to invest in both R&D, as well as manufacturing operations, and our new R&D center in Blackrock and €30 million investment in Enniscorthy are proof of BD’s long-term commitment to Ireland. We look forward to continuing our long tradition of high-tech medical device innovation and manufacturing here.”
The new 10,600 square-foot Blackrock R&D facility will house 35 high-tech workers and complements BD’s Limerick R&D facility, which employs over 300 people. The Blackrock R&D facility, according to the company, will focus on commercializing BD’s first on-body injection device, the BD Evolve on-body injector. The facility will also be the regional base of operations for BD’s sales, technical service, and corporate functional support teams.
The new €30 million investment to expand its existing Enniscorthy manufacturing facility will create about 85 new jobs. The 40,000 square-foot expansion will house operations to manufacture a new technology from BD’s Peripheral Intervention business.
Minister of State for the Department of Enterprise, Trade and Employment Neale Richmond TD told the press, “I am delighted with BD's announcement of a €4 million research and development facility in Blackrock, Dublin and additional €30 million expansion investment in Enniscorthy, Wexford. The projects will create more than 85 new jobs in Ireland with opportunities for our talented workforce to be part of exciting new medical advancements at BD. It is of course always great to see regional job creation, and the Government are always hugely supportive of such announcements. Thanks to all the executives at BD for your continued investment and trust in Ireland. I wish all the team the very best with both projects.”
IDA Ireland CEO Michael Lohan added, “BD has had a presence in Ireland for over 50 years, and these significant investments, adding a further 85 jobs and new facilities to its already substantial Irish operations and jobs, underscores the strategic importance of Ireland in BD’s global operations. It is proof of the company’s future commitment to the country and testament to Ireland and indeed our region’s continued attractiveness as a location for investment. I wish to assure BD of IDA Ireland’s continued support.’’
President of BD for Europe, Middle East and Africa Roland Goette said, “BD first established operations in Ireland in 1964, and since then has grown to four locations that employ more than 1,100 people across the country. Ireland has proven to be a smart place to invest in both R&D, as well as manufacturing operations, and our new R&D center in Blackrock and €30 million investment in Enniscorthy are proof of BD’s long-term commitment to Ireland. We look forward to continuing our long tradition of high-tech medical device innovation and manufacturing here.”
